Agarwal presented the TALAPRO-3 results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Agarwal ...

Following the FDA approval of lirafugratinib (Lyrfigtu) for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma, there are currently 3 FGFR2 inhibi ...

William A. Hall, MD, discussed the SOFT Preop study of preoperative SBRT vs conventional chemoradiation for pancreatic adenocarcinoma. The phase 3 NRG-GI003 trial showed no overall survival benefit ...

“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD. Meletios A. Dimopoulos, MD, explored how ...

“When we give the most effective therapy at the time of new diagnosis, we get the most value out of the effort and time that we and our patients are spending,” said Neeraj Agarwal, MD, FASCO.

Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.

In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.

In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA ...

Ethan B. Ludmir, MD, explains why advanced radiation techniques like protons fit nonoperative cholangiocarcinoma better than ...

The faculty then trace the development history of belantamab mafodotin. They describe the landscape around 2018, when daratumumab as a single agent produced a response rate close to 30% and only naked ...

Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.